Literature DB >> 28330648

Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes?

Gregory Giamouzis1, Javed Butler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28330648     DOI： 10.1016/S2213-8587(17)30089-X

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  4 in total

1.  Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.

Authors:  Magnus O Wijkman; Brian Claggett; Muthiah Vaduganathan; Jonathan W Cunningham; Rasmus Rørth; Alice Jackson; Milton Packer; Michael Zile; Jean Rouleau; Karl Swedberg; Martin Lefkowitz; Sanjiv J Shah; Marc A Pfeffer; John J V McMurray; Scott D Solomon
Journal:  Cardiovasc Diabetol       Date:  2022-06-18       Impact factor: 8.949

2.  Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study.

Authors:  Giuseppe Armentaro; Graziella D'Arrigo; Sofia Miceli; Velia Cassano; Maria Perticone; Raffaele Maio; Alberto Maria Marra; Franco Arturi; Antonio Cittadini; Giovanni Tripepi; Giorgio Sesti; Angela Sciacqua
Journal:  Front Physiol       Date:  2022-05-25       Impact factor: 4.755

Review 3.  The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis.

Authors:  Mona P Nasrallah; Charbel Abi Khalil; Marwan M Refaat
Journal:  Biomed Res Int       Date:  2017-11-14       Impact factor: 3.411

4.  Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.

Authors:  Hyue Mee Kim; In-Chang Hwang; Wonsuk Choi; Yeonyee E Yoon; Goo-Yeong Cho
Journal:  Sci Rep       Date:  2021-11-16       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.